EMERGENT BIOSOLUTIONS INC. Derivative Asset
EMERGENT BIOSOLUTIONS INC. (EBS) had Derivative Asset of $0 as of 2023-12-31, per its 10-K filed 2024-03-08.
Discontinued › Balance Sheet › Assets
us-gaap:DerivativeAssets · last filed 2024-03-08
- 2023-12-31: Derivative Asset $0.00.
- 2023-09-30: Derivative Asset $0.00.
- 2023-06-30: Derivative Asset $0.00.
- 2023-03-31: Derivative Asset $5.90M.
| Period end | Derivative Asset |
|---|---|
| 2023-12-31 | $0.00 10-K · filed 2024-03-08 |
| 2023-09-30 | $0.00 10-Q · filed 2023-12-11 |
| 2023-06-30 | $0.00 10-Q · filed 2023-08-09 |
| 2023-03-31 | $5.90M 10-Q · filed 2023-05-10 |
| 2022-12-31 | $8.50M 10-K · filed 2024-03-08 |
| 2022-09-30 | $0.00 10-Q · filed 2022-11-09 |
| 2022-06-30 | $6.30M 10-Q · filed 2022-08-02 |
| 2022-03-31 | $2.50M 10-Q · filed 2022-04-29 |
| 2021-12-31 | $0.00 10-K/A · filed 2023-12-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ENANTA PHARMACEUTICALS INC (ENTA) | United States | $0.349B | -6.72 |
| Larimar Therapeutics, Inc. (LRMR) | United States | $0.344B | -1.83 |
| Vogenx, Inc. (VOGX) | United States | $0.355B | |
| Benitec Biopharma Inc. (BNTC) | United States | $0.337B | -10.08 |
| BioAge Labs, Inc. (BIOA) | United States | $0.333B | -11.88 |
| BridgeBio Oncology Therapeutics, Inc. (BBOT) | United States | $0.320B | -3.35 |
| Evommune, Inc. (EVMN) | United States | $0.320B | -5.10 |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| Rezolute, Inc. (RZLT) | United States | $0.382B | -6.45 |